Product Description
Mechanisms of Action: Tubulin Inhibitor
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Chile | China | India
Approved Indications: None
Known Adverse Events: None
Company: Shanghai tenth People's Hospital
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Thyroid Cancer
Phase 1: Oncology Solid Tumor Unspecified|Oncology Hematological Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07056218 |
Low and Intermediate Risk | N/A |
Not yet recruiting |
Thyroid Cancer |
2026-12-15 |
2025-07-10 |
Primary Endpoints|Treatments |
|
NCT05078853 |
SCRC21021CTIL | N/A |
Recruiting |
Lymphatic Metastasis|Thyroid Cancer |
2024-12-31 |
2024-04-18 |
Primary Endpoints |
|
ChiCTR2000036620 |
ChiCTR2000036620 | N/A |
Not yet recruiting |
Thyroid Cancer |
2023-12-31 |
|||
ChiCTR2200055183 |
ChiCTR2200055183 | N/A |
Recruiting |
Thyroid Cancer |
2023-01-30 |
|||
ChiCTR-DDD-17013657 |
ChiCTR-DDD-17013657 | N/A |
Not yet recruiting |
Thyroid Cancer |
2018-06-30 |
|||
NCT02774291 |
NCI-2015-01781 | P1 |
Terminated |
Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified |
2020-07-01 |
2023-08-05 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT02390739 |
15-C-0090 | P2 |
Withdrawn |
Thyroid Cancer |
2017-03-22 |
2019-03-20 |
Treatments |